Clinical Trials Browser

Phase 1/2 × grapiprant × Clear all

NCT05041101 2025-06-13

Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer

Phase 1/2 Terminated

6 enrolled 11 charts

Inflammatory Breast Neoplasms

NCT03696212 2021-02-21

Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma

Phase 1/2 Terminated

Non-small Cell Lung Cancer Adenocarcinoma